Despite improved preoperative staging limited metastatic spread to the pelvic lymph nodes occurs in up to 5% of patients undergoing radical prostatectomy. In this study, distinct pathological aspects of solitary lymph node metastasis were addressed with regard to treatment outcome.
Results
A total of 51 (58%) of lymph node deposits appeared to be true micrometastases with a diameter of up to 2 mm; 25% were even smaller than 1 mm in diameter. Gross infiltration of the lymph node was noted in 43 (49%), capsular penetration in 38 (43%) cases. Infiltration of the lymphoreticular tissue was oberved in 80 (91%), while 8 (9%) micrometastases were considered to be unequivocally located within a subcapsular or medullary sinus. Five-and 10-y tumorspecific survival of patients undergoing radical prostatectomy was 94 and 51% compared to 50 and 17% for those receiving AD (log rank, P ¼ 0.025). Of the histopathological parameters analysed, only diameter of the lymph node deposit predicted tumor specific outcome. Mean tumor-specific survival of patients with micrometastasis was 123 months compared to 98 months for the larger ones (P ¼ 0.005).
Conclusion
The diameter of the metastatic deposit of solitary lymph node metastases appears to be an important predictor of tumor-specific survival in patients with prostate cancer. Multivariate analysis will further clarify the role of this parameter in this patient cohort.
Prospective analysis of the time to normalization of serum testosterone following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial utilizing intermittent hormonal therapy Introduction This is the largest study presented to date evaluating the timing of testosterone (T) rise following cessation of GnRH therapy. This is also the only trial to look at this with patients who have biochemical recurrence only (no metastatic disease on radiographic imaging). This is the only trial evaluating the timing of testosterone rise in which all patients received 6 months of GnRH-A. The findings in this study support and build on the findings of the other four published studies and two case series.
Method
A total of 126 GnRH analogue naive patients (pts) at seven centers with rising PSA following definitive local treatment for prostate cancer, but no radiographic evidence of disease were enrolled on a double-blinded randomized clinical trial of intermittent hormonal therapy. After 6 months of a GnRH analogue alone (leuprolide or goserelin), pts received either thalidomide 200 mg daily or placebo. When the PSA rose to 5 ng/dl or baseline (whichever was lower), pts who still had no radiographic evidence of disease commenced another 6 months of hormonal therapy, then crossed over to the opposite oral treatment. T measurements were taken every 3 months on GnRH analogue therapy and monthly on oral study drug. We report here results of the time to T rise in pts after treatment with the initial 6 months or hormonal therapy, measured from the day of the last 3-month treatment with a GnRH analogue. Of the initial 126 pts, 80 patients had completed the initial 6 months of GnRH therapy and were evaluable. A multivariate analysis was performed with the following variables: age, Gleason score, on study PSA and T, prior definitive treatment (surgery, radiation, both), and any prior hormonal therapy.
Results
There were no factors identified which had an impact on the time to T rise above castrate levels (50 ng/dl). There were two factors associated with a longer time to rise of T to normal levels in this population: age greater than 67 and low baseline T levels (50-211 ng/dl). The median time to normal T in pts 49-66 y old was 27.7 weeks, while pts over 66 y had a median recovery time of 29.7 weeks (P ¼ 0.08). In addition, none of the five patients with low baseline testosterone levels rose to 211 or higher, while the median time of rise to that level for the remaining 56 pts with baseline T data available who had normal baseline T was 28.6 weeks (P ¼ 0.009). The median time to rise in T to 450 ng/dl in this group was 24.9 weeks.
Conclusions
Thus, after 6 months of GnRH therapy in hormone therapy naive pts who started with normal T levels, T remained suppressed in the castrate range for an average of another 3 months and subsequently rose to normal within one additional month. These data may impact clinical trial design for intermittent hormonal therapy trials. 
Background
Alterations in ultrastructure occur in the development of solid organ disease. These changes influence cell function and convey information on pathogenesis. While much research is focused on the cellular processes involved in the development benign and malignant prostatic disease processes, little is known about the role played by collagen. Scanning electron microscopy (SEM) has played a major role in defining the three-dimensional collagen network in solid organs, while transmission electron microscopy (TEM) has helped elucidate the organisation of fibres.
Objectives
To determine the ultrastructural pattern of the normal and diseased prostate and to develop a means of measuring these features.
Methods
Prostatic tissue was obtained from radical cystoprostatectomy (benign prostate), transurethral resection of prostate (benign prostatic hyperplasia (BPH)) and radical prostatectomy (prostate cancer). Diagnosis was confirmed on light microscopy prior to processing of tissue samples. Samples were fixed in 2% glutaraldehyde solution and macerated in a 10% aqueous solution of NaOH for 72 h. They were postfixed in osmium tetroxide, mounted on aluminium stubs, gold-coated and examined using SEM. Digital images were obtained directly and measurements performed on screen. Specimens were processed for TEM following maceration for 24 h, revealing the histological nature of the tissue after digestion.
Results
Collagen fibres were seen to be nonbranching and running parallel along the circumference of each acinus.
Conclusions
Using the tissue maceration technique, discrete ranges of measurement of collagen fibre thickness were obtained for normal, hyperplastic and neoplastic glands. These findings were confirmed using TEM, which showed a definite pattern of collagen distribution around each acinus. This technique may provide a useful model for the assessment of response to treatment and the study of trophic mechanisms in benign and malignant growth of the prostate and assist in diagnosis when the volume of tissue for examination is limited. Background Angiogenesis appears to be critical for tumour growth and metastasis in prostate adenocarcinoma (CaP). The identification of the switch to the angiogenic phenotype may help to direct antiangiogenic therapies at specific time points in CaP development and progression.
Objectives
To determine the temporal relationship of the switch to the angiogenic phenotype and the differential expression of the angiogenic promoters basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in a transgenic murine model of CaP (TAGMAP).
Methods
A transgene constructed using a prostate-specific protein of 94 amino acids gene promoter/enhancer region directed targeting of expression of a full length of SV40 Tag (T and t antigens) gene to the prostate. For enhancing transgenic expression by intron sequences, a second trangene was constructed linking the promoter/enhancer-exon1-part of intron 1 and exon 2 followed by the SV40 Tag gene with the same reading frame. After breeding with the wild type of (C57BL/6 x CBA) F1 hybrids, three transgenic founder breeding lines (F0 of A, B, and C) were characterized and successfully established. Immunohistochemical analyses of bFGF, VEGF, and microvessel density (MVD) were performed and correlation with pathological findings was performed.
Results
By 12 weeks of age, changes of low-grade and subsequent high-grade prostatic intraepithelial neoplasia (LGPIN and HGPIN, respectively) were present and subsequent development of well-and poorly differentiated CaP occurred. By ANOVA, the trend in protein expression of bFGF and VEGF was increased from HGPIN to poorly differentiated CaP (Po0.0001). MVD was increased in poorly differentiated CaP.
Conclusions
Upregulation of angiogenic promoters appear to occur early in the precursor lesion HGPIN. The switch to the angiogenic phenotype in this TAGMAP appears to occur with the development of CaP. Background Prostate-specific antigen (PSA) at prostate cancer (PCa) diagnosis has been shown to predict disease recurrence after radial prostatectomy (RP). This has recently been questioned, as the rate of biochemical disease recurrence has been suggested to be unchanged for PSA values between 2.0 and 9.0 ng/ml. The purpose of this study was to test the hypothesis that PSA values between 2.0 and 9.0 ng/ml at diagnosis are unrelated to different rates of biochemical disease recurrence after RP.
Methods
The study population consisted of 4187 consecutive patients who were treated with RP at four institutions between 1983 and 2000. Pretreatment PSA, clinical stage, and primary and secondary biopsy Gleason grades were documented in 3830 patients. After excluding those who received neoadjuvant hormonal therapy or who had missing clinical data, 3045 patients were evaluable. We limited the analysis to the 1756 patients with a pretreatment PSA between 2 and 9 ng/ml: Cox models were then used to determine the risk of recurrence following surgery across this PSA range.
Results
The target cohort consisted of 1756 patients, in whom follow-up ranged from 1 to 148 months (median 21).
Overall, 184 biochemical recurrences were recorded, and six treatment failures were defined based on intraoperative diagnosis of nodal metastasis. In multivariate Cox regression models, serum PSA was an important predictor of treatment failure, after accounting for primary and secondary Gleason grades, and clinical stage. For pretreatment PSA values between 2 and 9 ng/ml, the rate of biochemical recurrence after RP increased by a value of 1.53 (95% CI: 1.22-1.95) for each ng/ml of PSA. Freedom from recurrence at 5 y was estimated at 89% (95% CI: 85-92) for a PSA of 2 ng/ml, vs 69% (95% CI: 61-76) for a PSA of 9 ng/ml.
Conclusions
In men with clinically localized prostate cancer who are treated with RP, the rate of disease recurrence increases in proportion to PSA value at diagnosis. For PSA levels between 2 and 9 ng/ml, this rate increases by a value of 1.5 for each ng/ml of pretreatment PSA. This suggests, that a man with a PSA value of 9 has an over 10-fold higher risk of biochemical disease recurrence, than a man with a PSA value of 2, after controlling for Gleason primary and secondary grades and for clinical stage. This heterogeneity of outcomes across pretreatment PSA levels between 2 and 9 ng/ml warrants consideration when diagnostic, staging and treatment choices are made. 
Objectives
To determine if single nucleotide polymorphic variants in the 3 0 UTR of p21 cip1 and in codon 109 of p27 kip1 are associated with advanced prostate cancer in a EuropeanAmerican population.
Materials and methods
Genomic DNA was isolated from 96 patients with advanced prostate cancer and 106 cancer-free controls. All patients were receiving hormone ablation. Patients had either PSA 450 ng/ml or documented metastatic disease. Entry criteria were designed to ensure that all patients had advanced disease. Controls were all 75 y of age or older, had a negative DRE and had a PSA o4.0 ng/ml. Entry criteria were designed to ensure that no control had or was at risk of developing clinically aggressive prostate carcinoma. p21 cip1 and p27 kip1 genotypes were determined using a PCR amplification and restriction digestion assays with PstI and BglI respectively. p21 cip1 variant changes a cytosine to thymine 20 bp 3' of the stop codon thereby removing a PstI site. Genotypes were scored as CC, CT and TT on the basis of the digestion products. Similarly, the p27 kip1 variant changes a thymine to a guanine, which results in a valine to glycine change at codon 109. The T to G change adds a BglI site. Genotypes were scored as VV, VG, or GG again on the basis of the digestion products.
Results

The p21
cip1 genotypes CT and TT were associated with an increased risk of advanced prostate carcinoma compared to the CC genotype (OR 2.24: 95% CI ¼ 1.02-4.95). The p27 kip1 genotype VV was also associated with an increased risk of advanced prostate carcinoma (OR 1.95: 95% CI ¼ 1.09-3.47). Both associations were stronger in those patients with androgen-independent disease (OR 2.88: 95% CI ¼ 1.19-6.97 and OR 2.11: 95% CI ¼ 1.05-4.22 for p21 cip1 and p27 kip1 , respectively). In addition, the association of the p27 kip1 polymorphism was stronger in the cohort of patients under the median age of diagnosis (OR 2.23: 95% CI ¼ 1.08-4.59).
Conclusions
These results suggest that in a European-American population, p21 cip1 and p27 kip1 variants are associated with advanced prostate cancer. Analysis of p21 cip1 and/ or p27 kip1 genotypes may prove useful in determining which patients are at risk for developing advanced prostate carcinoma and therefore might benefit the most from aggressive screening, prophylaxis and/or treatment.
Abstracts
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Significance of prostate-specific antigen (PSA) nadir measured by an ultrasensitive assay for predicting biochemical failure after radical prostatectomy 
Background and objectives
Radical prostatectomy (RP) is considered to be a better treatment choice for organ confined prostate cancers. However, as PSA elevation after operation occurs in 15-40% of patients, it is important to predict biochemical failure accurately. In cases of biochemical failure, salvage radiotherapy is the therapeutic choice. As reported in several studies salvage radiotherapy conducted at an earlier stage can give local control with better effectiveness. Despite clinicopathologic findings like Gleason score, pathologic stage, surgical margin and so on, being very important factors to estimate biochemical failure, these factors vary among pathologists. To predict biochemical failure, we analyzed the PSA change in an ultrasensitive range after radical prostatectomy.
Patients and methods
From 1998, 98 patients who underwent radical prostatectomy were followed up at least for 12 months in our hospital. A total of 12 patients who underwent preoperative endocrine therapy and four patients with lymph node metastasis were withdrawn from the study. PSA evaluation was performed every 2-3 months for the first 2 y using ultrasensitive PSA assay (DPC Immulite HS-PSA kit). We defined the definition of biochemical failure at a PSA value of 0.10 ng/ml. Cases with over 18 months PSA doubling time were temporary categorized as unclassified and followed up.
Results
Of the analyzed 82 patients, 25 (30.5%) developed biochemical failure and the PSA figures of 11 patients remained at 0.1 ng/ml or above. In 16 patients out of the other 71, the nadir was at one stage below 0.1 ng/ ml; however, it then exceeded that value. PSA doubling time (PSADT) was also analyzed in the range of ultrasensitive assay. PSA figures of four patients showed a very slow PSADT over 18 months and the PSA figure remained at less than 0.2 ng/ml for 4 y. These cases were temporary categorized as unclassified. The 82 patients were classified into three groups according to the PSA nadir measured by the ultrasensitive assay: group 1 (n ¼ 52) 'less than 0.02ng/ml'; group 2 (n ¼ 14) '0.021-0.04 ng/ml'; group 3 (n ¼ 16) 'over 0.04 ng/ml'. Only four patients (7.7%) in group 1 experienced biochemical relapse compared to 13 in group 3 (81.3%). In group 2, eight patients (57.1%) developed biochemical failure.
Conclusion
Ultrasensitive PSA nadir is a very important and useful factor in predicting biochemical failure after radical prostatectomy. By using this parameter, salvage radiotherapy can be performed at a much lower PSA level. 
Background
Experimental and epidemiological studies have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in the prevention of human cancers. NSAIDs inhibit the cyclooxygenase (COX) enzyme, the enzyme responsible for the conversion of arachidonic acid to prostaglandins.
Objectives
Our objectives were to examine the effects of the selective COX-2 inhibitor, NS-398, on prostate cancer cell lines and to perform global gene expression analysis for the discovery of novel pathways and mechanisms of COX-2 inhibition.
Methods
Cell proliferation and viability was assessed by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and by trypan blue exclusion at multiple concentrations of NS398. The cell cycle profile was analyzed by flow cytometry. From treated and untreated cells, cDNA probes were made from extracted total RNA. These probes were hybridized to our prostate expression database (PEDB) spotted microarray composed from a nonredundant set of 6000 prostate-derived cDNA clones identified from the prostate transcriptome. Individual clone inserts were amplified by PCR, purified, and spotted in duplicate onto coated glass microscope slides. For each experiment, each cDNA was represented twice on each slide, and the experiments were performed in duplicate, producing four data points per cDNA clone and hybridization probe. Standard Northern and Western analyses were performed for confirmation of gene expression changes.
Results
Cell proliferation and viability in prostate cancer cell lines was significantly decreased by NS398 treatment compared with vehicle-treated (control) cells. The effect was both time-and dose-dependent. Cell cycle analysis of vehicle-treated LNCaP cells revealed 63.3, 12.2, and 24.5% in G1/G0, G2, and S phase, respectively, while NS398 treatment caused marked G1/G0 arrest in LNCaP cells with 87.3, 12.1, and 0.6% in G1/G0, G2, and S phase, respectively. By microarray analysis, insulin-like growth factor binding protein-3 (IGFBP3) was the most upregulated gene. Several genes associated with cell cycle and apoptosis were up-or down-regulated by microarray analysis, including proliferating cell nuclear antigen (PCNA), mitotic arrest deficient 2 (MAD2), inhibitor of DNA binding-1 (ID1) and -3 (ID3). Additionally, several genes associated with metastases and invasion such as matrix metalloproteinase 7 (MMP7) and the serine protease family (kallikrein 2, kallikrein 3 [PSA], TMPRSS2) were markedly downregulated with COX-2 inhibition in LNCaP cells. Western and Northern analyses confirm these gene expression changes.
Conclusions
COX-2 inhibition causes cell cycle changes in prostate cancer cells in vitro. Global gene expression analysis not only supports these cell cycle changes but also reveals novel mechanisms of COX-2 inhibition. Several of our gene expression changes have been reported in previous work with colon carcinoma cells; however, our preliminary studies presented here also reveal heretofore unreported changes in carcinoma cells treated with COX-2 inhibitors. For instance, the serine proteases are highly regulated by the androgen-receptor, suggesting that COX-2 inhibition may decrease prostate cancer cellular proliferation through the androgen-receptor pathway. Parallel experiments are underway with commercially available COX-2 inhibitors, rofecoxib (Vioxx 
